ATE552824T1 - Kontrollierte und kontinuierliche verabreichung von rifaximin - Google Patents

Kontrollierte und kontinuierliche verabreichung von rifaximin

Info

Publication number
ATE552824T1
ATE552824T1 AT03810439T AT03810439T ATE552824T1 AT E552824 T1 ATE552824 T1 AT E552824T1 AT 03810439 T AT03810439 T AT 03810439T AT 03810439 T AT03810439 T AT 03810439T AT E552824 T1 ATE552824 T1 AT E552824T1
Authority
AT
Austria
Prior art keywords
gum
rifaximin
controlled
infections
food
Prior art date
Application number
AT03810439T
Other languages
English (en)
Inventor
Piero Chiarelli
Renzo Dalseno
Original Assignee
Fadim S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITFI20020212 external-priority patent/ITFI20020212A1/it
Priority claimed from ITMI20022438 external-priority patent/ITMI20022438A1/it
Priority claimed from ITPI20030005 external-priority patent/ITPI20030005A1/it
Priority claimed from ITPI20030013 external-priority patent/ITPI20030013A1/it
Application filed by Fadim S R L filed Critical Fadim S R L
Application granted granted Critical
Publication of ATE552824T1 publication Critical patent/ATE552824T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063Periodont
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03810439T 2002-11-05 2003-11-05 Kontrollierte und kontinuierliche verabreichung von rifaximin ATE552824T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITFI20020212 ITFI20020212A1 (it) 2002-11-05 2002-11-05 Protesi gengivale interdentale (gengiva artificiale).
ITMI20022438 ITMI20022438A1 (it) 2002-11-18 2002-11-18 Composizione a base di rifaximina per la profilassi del cavo orale.
ITPI20030005 ITPI20030005A1 (it) 2003-01-14 2003-01-14 Materiale per rilascio di farmaci in cerotti per il derma
ITPI20030013 ITPI20030013A1 (it) 2003-02-21 2003-02-21 Rilascio controllato e continuato di rifaximina ed altre
PCT/EP2003/012346 WO2004041240A1 (en) 2002-11-05 2003-11-05 Controlled and continued delivery of rifaximin and/or other substances

Publications (1)

Publication Number Publication Date
ATE552824T1 true ATE552824T1 (de) 2012-04-15

Family

ID=32314924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810439T ATE552824T1 (de) 2002-11-05 2003-11-05 Kontrollierte und kontinuierliche verabreichung von rifaximin

Country Status (6)

Country Link
US (1) US8758804B2 (de)
EP (1) EP1560566B1 (de)
AT (1) ATE552824T1 (de)
AU (1) AU2003276254A1 (de)
ES (1) ES2385477T3 (de)
WO (1) WO2004041240A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
IT201800003872A1 (it) * 2018-03-22 2019-09-22 Dtech Soc A Responsabilita Limitata Prodotto per il trattamento terapeutico per la prevenzione e cura di patologie del cavo orale, dei denti e degli impianti dentali

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6300M (de) * 1967-03-29 1968-09-09
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
US4904247A (en) * 1984-08-31 1990-02-27 Kendall Company Pressure-sensitive hydrophilic laminate structures for use in wound dressing, transdermal and topical drug delivery
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
BR9305045A (pt) * 1992-12-15 1994-07-26 Johnson & Johnson Laminado, compósito, processo para formar um laminado de hidrogel, bandagem e método de cobrir uma ferida
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US6194455B1 (en) * 1999-05-28 2001-02-27 Marie Madeline Wharton Topical medicament for treating skin ulcers
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents

Also Published As

Publication number Publication date
WO2004041240A1 (en) 2004-05-21
EP1560566A1 (de) 2005-08-10
ES2385477T3 (es) 2012-07-25
US8758804B2 (en) 2014-06-24
EP1560566B1 (de) 2012-04-11
US20060110447A1 (en) 2006-05-25
AU2003276254A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
DE60032691D1 (de) Brausetablette für die sublinguale, bukkale und gingivale verabreichung von fentanyl
MY151430A (en) Anti-caries oral care compositions with xylitol
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
IL176449A0 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
MY148458A (en) Oral compositions containing extracts of rosmarinus and related methods
BR9506924A (pt) Composição farmacêutica sublingual ou bucal e utilização do trans-5-cloro-2-metil-2,3,3a, 12b-tetraidro-1h-dibenz(2,3:6,7) oxepino(4,5-c)pirrol
DK1471890T3 (da) Farmaceutisk doseringsform til mukös afgivelse
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
Mohan et al. Pharmacological agents in dentistry: a review
BRPI0413566A (pt) composição de branqueamento de dentes, e, métodos de branqueamento de uma superfìcie de um dente em um cavidade oral de um paciente e de branqueamento de um dente em um mamìfero
DE50010125D1 (de) Atraumatischer approximalraumerweiterer
ATE552824T1 (de) Kontrollierte und kontinuierliche verabreichung von rifaximin
Kumar LS Pharmaceuticals: tetracyclines and periodontal disease
CA2547654A1 (en) Use of osteopontin in dental formulations
RU2005112984A (ru) Способ лечения хронического пародонтита
IL157707A0 (en) Composition and method for treatment or prevention of oral cavity disorders by local forms of drug delivery
AU3162701A (en) Pharmaceutical compositions for the topical administration in the oral cavity ofnon-steroid anti-inflammatory drugs useful for the stomatologic, mouth and oral cavity anti-inflammatory and analgesic therapies
RU2003101441A (ru) Способ лечения деструктивных форм периодонтита
Guzeldemir-Akcakanat Systemic antibiotics in the treatment of periodontitis
Stanisław et al. Periodontitis, Blood Pressure, and the Risk and Control of Arterial Hypertension: Epidemiological, Clinical, and Pathophysiological Aspects—Review of the Literature and Clinical Trials
UA57223U (ru) Способ лечения больных генерализованным пародонтитом c хроническим и обостренным течением
Vitaya Management of developmental anomalies in the maxillary incisors: case report
Masliy et al. The development of dental drug in the form of medicated chewing gum
KR20200112478A (ko) 스테로이드, 라이신 및 비타민 c를 유효성분으로 포함하는 치주질환 예방 또는 치료용 약학적 조성물
Mammdoh Efficacy of Azithromycin in Comparison with Metronidazole in the Treatment of Chronic Periodontitis